Guideline-Concordant Statin Therapy Use in Secondary Prevention: Should the Medical Community Wait for Divine Intervention?
- PMID: 35512861
- DOI: 10.1016/j.jacc.2022.02.042
Guideline-Concordant Statin Therapy Use in Secondary Prevention: Should the Medical Community Wait for Divine Intervention?
Keywords: atherosclerosis; predictors; prevention; secondary prevention; statins.
Conflict of interest statement
Funding Support and Author Disclosures Dr Virani has received institutional grant and research support from the Department of Veterans Affairs, The National Institutes of Health (NIH), the World Heart Federation, and The Jooma and Tahir Family; and has received an honorarium from the American College of Cardiology as Associate Editor of Innovations. Dr Ballantyne has received institutional grant and research support from Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, NIH, the American Heart Association, and the American Diabetes Association; and has provided consulting for Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Matinas BioPharma, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo. Dr Petersen has reported that she has no relationships relevant to the contents of this paper to disclose.
Comment on
-
High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.J Am Coll Cardiol. 2022 May 10;79(18):1802-1813. doi: 10.1016/j.jacc.2022.02.048. J Am Coll Cardiol. 2022. PMID: 35512860 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical